InDex Pharmaceuticals Holding AB (1NP1) Price & Analysis

5 Followers

1NP1 Stock Chart & Stats

€1.68

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€1.68

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€1.43 - €3.29

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€140.76M

Enterprise Value€1.53K

Total Cash (Recent Filing)€305.70M

Total Debt (Recent Filing)€1.70M

Price to Earnings (P/E)―

Beta0.11

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.56

Shares Outstanding86,697,700

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.76

Price to Sales (P/S)290.28

P/FCF Ratio-90.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low LeverageMinimal leverage reduces refinancing and solvency risk, preserving financial flexibility while the company advances its development programs. The sizable equity base provides a stronger capital structure than the loss profile alone would suggest, although returns remain negative.

Focused Immunology PipelineA defined therapeutic focus can concentrate scientific and regulatory resources around a coherent disease-area strategy. Cobitolimod gives the company a lead asset with a specific ulcerative colitis application, creating a clear basis for development and potential partnering.

Partnering-based Commercialization ModelAn out-licensing model can provide multiple potential economic pathways without requiring InDex to build large-scale commercial manufacturing or direct sales operations. If development progresses and partners commercialize assets, milestones and royalties could support longer-term revenue generation.

Bears Say

Persistent Large LossesThe scale of ongoing losses indicates that current operations are far from self-funding and that the cost base substantially exceeds generated revenue. Persistent negative earnings can erode the capital base over time and increase dependence on successful pipeline execution or external financing.

Highly Volatile RevenueLarge swings in reported revenue undermine visibility into the company’s ability to generate recurring commercial income. The reversal from positive prior-period revenue to negative TTM revenue suggests that partnering-related receipts are inconsistent, making future funding and operating planning less predictable.

Ongoing Cash BurnContinued negative operating and free cash flow shows that the business is not currently financing its activities internally. Even with low debt, sustained cash consumption can reduce available capital and leave future progress dependent on existing funds, financing, or successful partnering proceeds.

1NP1 FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was €1.43 and its highest was €3.29 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is €140.76M.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

InDex Pharmaceuticals Holding AB’s upcoming earnings report date is Oct 15, 2026 which is in 26 days.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Jul 09, 2026. The company reported -€0.092 earnings per share for the quarter.

Is InDex Pharmaceuticals Holding AB overvalued?

According to Wall Street analysts InDex Pharmaceuticals Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -€0.092 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in DE:1NP1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InDex Pharmaceuticals Holding AB

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.